Kahina is currently responsible for building a collaboration platform to unlock new ways to expand the applicability of mRNA-based medicines. This cross-sector effort will advance Merck KGaA Darmstadt Germany’s offerings for the mRNA market via novel lipid nanoparticle formulation and potentially add therapeutic modalities to the Healthcare pipeline. With a proven track record of advancing cross-functional projects, Kahina has been a driving force of this cross-sector initiative from its origin, bringing to life the One Merck vision and making innovation happen. She is also member of the Life Science Chief Technology Office Leadership Team.
Kahina joined Merck KGaA Darmstadt Germany in 2016 as part of the Global Graduate Program of Inhouse Consulting. She continued her career in Group Strategy as Group Portfolio Manager and Strategy Liaison for Healthcare. In 2020, she transitioned to the Healthcare Sector and joined the Research Leadership Team where she was in charge of driving the Discovery Strategy. For one year, she has led the Strategic Innovation team, responsible for a worldwide portfolio of academic partnerships.
Kahina holds a Doctor title of Pharmacy from Paris Saclay University with a major in Health Economics. Additionally, she concluded two years of Business Administration education from HEC Paris and MIT Sloan.